Canbiola Creates Fully Independent Board of Directors
October 15 2019 - 9:22AM
InvestorsHub NewsWire
Canbiola Creates Fully Independent Board of Directors
Changes and Additional Appointments
Satisfy a Criteria for Potential Nasdaq
Listing
HICKSVILLE, NY -- October 15, 2019 --
InvestorsHub NewsWire -- Canbiola, Inc.
(OTCQB: CANB) (“Canbiola” or the
“Company”), a developer, manufacturer and seller of a
variety of hemp-derived THC-Free Cannabidiol (CBD) Isolate products
such as oils, drops/tinctures, creams, moisturizers, chews, and
capsules is pleased to announce the appointments
of SenatorRon Silver, James Murphy and Alger Boyer Jr.
to its Board of
Directors.
Canbiola Chief
Executive Officer Marco Alfonsi commented, “We are honored to have
Ron, James, and Alger join our team as members of our Board of
Directors. We were seeking independent Board members who share in
the excitement, acceptance, and vision for CBD products. Their
combined 50+ years of business experience, particularly in
operations, business development and legal regulatory and
governmental processes is invaluable and we look forward to their
advice and guidance. Given our traction of more than 400% growth to
greater than $1.1 million revenue in the first half of 2019, I
believe Canbiola is on the cusp of creating significant value for
its shareholders.”
Senator Ronald A.
Silver was first elected to the Florida House
of Representatives in 1978 and continued his tenure in that body
until 1992. While in the Florida House Silver served in major
positions including Majority Whip (1984-1986) and Majority Leader
(1986-1988). He also chaired various committees including the
Select Committee on Juvenile Justice, Criminal Justice, Ethics and
Elections and the subcommittee of Appropriations on General
Government. He was then elected to the Florida Senate in 1992 and
subsequently re-elected, serving as the Majority (Democratic)
leader for the 1994 session. During his last term in the
Senate, he was designated by both the House and Senate as the Dean
of the Legislature recognizing his standing as the longest-serving
member. His career as a lawmaker has yielded a vast and extensive
knowledge of public policy issues and the legislative process,
allowing him to be an advocate and servant for his diverse
community. Throughout his tenure in the House and Senate, Mr.
Silver has been known to tackle tough issues, transcend
partisanship and build strong coalitions and in addition served on
the Judiciary Committee, which heard all condominium issues. As
Senator, he served on a variety of committees and was chairman of
both the Appropriations Subcommittee on Health and Human Services
and Criminal Justice. His career in the Senate has earned praise
from his colleagues, in both the legislature and other branches of
government throughout the nation. In 1993 Mr. Silver was elected
Chairman of the Southern Legislative Conference (17 Southern
States) of the Council of State Governments. Most recently, a new
prescription drug plan of Medicare-eligible senior citizens in the
State of Florida has been named "Silver Saver" in his
honor. Since his retirement from the Senate
in 2002, Mr. Silver also functions as President of his own
consulting firm (Ron Silver & Associates) and maintains his law
practice in Miami Beach, Florida.
James F. Murphy brings
more than 40 years of investigative and consulting experience as
the Founder and President of Sutton Associates. From 1980 to 1984,
Mr. Murphy was an Assistant Special Agent in Charge with the
Federal Bureau of Investigation, responsible for a territory
encompassing more than seven million people. His investigative
specialties included organized crime, white-collar crime, labor
racketeering, and political corruption. From 1976 to 1980, Mr.
Murphy was assigned to the Office of Planning and Evaluation at FBI
headquarters, Washington, D.C. In this capacity, he evaluated and
recommended changes in the FBI’s administrative and investigative
programs. Since entering the private sector in 1984, Mr. Murphy has
advanced the industry by developing systematic and professional
protocols for performing due diligence, as well as other
investigative services.
Alger Boyer, Jr:
President & CEO of Advance Care Medical, Inc. - Mr. Boyer has
over 25 years of Wall Street experience having worked on both the
investment side as well as the banking side of the business. Most
recently he served as Head of Equities for the New York-based
investment bank H.C. Wainwright & Co. where he had overseen
efforts in capital markets, sales, and trading. Prior to that, he
worked and or supervised teams at Rodman & Renshaw,
Oppenheimer, Piper Jaffray, and Credit Suisse in New York, San
Francisco, and Minneapolis. In his various roles, he has advised
hundreds of companies in their financing efforts both publicly and
privately. Mr. Boyer has numerous securities licenses and is a
graduate of the University of California at
Berkeley.
Additionally, Mr.
Johnny J. Mack Ph.D. has resigned from his Canbiola positions of
President, Chief Operating Officer and Director and Mr. Joe
Hunsberger has resigned as a Director of
Canbiola.
About Canbiola, Inc.
Canbiola, Inc.
(OTCQB: CANB)
is a vertically integrated conglomerate specializing in the
manufacturing, formulation, and sale of THC-Free Cannabidiol
(CBD) Isolate products such as oils, drops/tinctures, gels, creams,
moisturizers, chews, and capsules. All Canbiola products are
organic and Non-GMO, free of impurities and contaminants, and
formulated with the finest ingredients to the highest manufacturing
standards. All products are certified for purity and accuracy
by third-party laboratory
verification.
Canbiola pursues an
aggressive growth strategy through the continual development of
proprietary products and the expansion of its offerings via
strategic acquisitions in the healthcare and CBD
industries.
Canbiola has created
several innovative CBD product lines, marketed through targeted
channels including:
The Canbiola clinical
line, which is marketed and promoted through healthcare
practitioners in the medical
setting.
The Pure Leaf Oil
(consumer brand) and Seven Chakras (spa brand) lines are sold
through both online and brick & mortar retail
outlets.
Canbiola’s
state-of-the-art manufacturing facility in Lacey, WA is operated by
Pure Health Products LLC (PHP), a wholly-owned subsidiary that
produces all of the Company’s CBD Isolate products, in addition to
providing private label and white label solutions for companies
looking to add high-quality CBD items to their offerings. Canbiola
is passionate about improving people’s lives and we take pride in
providing pure CBD products infused with organic and natural
ingredients. We want customers to know that they are buying
lab-tested, high-quality natural products at a great
price.
Canbiola’s Radical
Tactical LLC subsidiary produces CBD products in other forms
including vapes and gums.
Duramed Inc. and
Duramed NJ LLC, wholly-owned subsidiaries of Canbiola, further the
mission of providing innovative products designed to improve
people’s lives, aiming to reduce their use of opioid substances
through the utilization of durable medical devices. This product
line includes an FDA-approved wearable low-intensity ultrasound SAM
(Sustained Acoustic Medicine) device delivering multi-hour
treatment intended to accelerate healing, improve function for
musculoskeletal injuries (muscle, tendon, ligament) and reduce
chronic pain (without opioid pain
medication).
With the creation of
its newest wholly owned subsidiary, NY Hemp Depot LLC, Canbiola has
attained complete vertical integration, allowing it to fully
control the supply chain from seed to sale, develop customized
products and maximize profit margins. Through the utilization of
its newly acquired NY State Hemp Cultivation License, the Company
contracts with farmers throughout the state of NY to cultivate
specific strains of hemp, which is then processed into CBD Isolate
products to Canbiola’s exacting manufacturing standards and
specifications at the Company’s laboratory and production
facility.
For more information
about Canbiola, Inc., please visit: Canbiola.com
Forward-Looking
Statements
Forward-looking
statements and risks and uncertainties discussed in this letter
contain forward-looking statements. The words "anticipate,"
"believe," "estimate," "may," "intend," "expect," and similar
expressions identify such forward-looking statements. Expected,
actual results, performance, or achievements could differ
materially from those contemplated, expressed, or implied by the
forward-looking statements contained herein. Forward-looking
statements are subject to a number of risks and uncertainties,
including but not limited to, risks and uncertainties associated
with, among other things, the impact of economic, competitive, and
other factors affecting our operations, markets, products, and
performance. The matters discussed herein should not be construed
in any way, shape or manner of our future financial condition or
stock price.
Follow Canbiola
on:
Twitter
@CanbiolaHealth
Instagram @canbiola.inc
or @canbiola_cbd or
@canbiola_medical_cbd
Investors and
Media:
IR@canbiola.com
(516)
595-9544
CAN B (QB) (USOTC:CANB)
Historical Stock Chart
From Aug 2024 to Sep 2024
CAN B (QB) (USOTC:CANB)
Historical Stock Chart
From Sep 2023 to Sep 2024